Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
DBV Technologies
DBVCurrent price
0.66 EUR
-0.01 EUR (-1.50%)
Last closed
0.63 USD
Company
www.dbv-technologies.com
ISIN
US23306J1016
Sector
Healthcare
Industry
Biotechnology
Exchange
Euronext Paris
Capitalization
74 329 648 USD
Yield for 12 month
-63.95 %
1Y
3Y
5Y
10Y
15Y
DBV
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. Address: 177-181 Avenue Pierre Brossolette, Montrouge, France, 92120
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
+15 728 000 USD
Last Year
+4 800 000 USD
Current Quarter
–
Last Quarter
+1 161 000 USD
Current Year
+20 225 000 USD
Last Year
-16 534 000 USD
Current Quarter
–
Last Quarter
-2 994 999 USD
Key Figures DBV
1 year
3 years
5 years
10 years
EBITDA
-79 693 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-34.89 %
PEG Ratio
–
Return On Equity TTM
-72.64 %
Wall Street Target Price
6 USD
Revenue TTM
13 814 000 USD
Book Value
1.46 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-49.3 %
Dividend Yield
–
Gross Profit TTM
4 844 000 USD
Earnings per share
-0.91 USD
Diluted Eps TTM
-0.91 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics DBV
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DBV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:2
Payout Ratio
–
Last Split Date
07.06.2024
Dividend Date
–
Stock Valuation DBV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
5.3807
Enterprise Value EBITDA
-2.0735
Price Book MRQ
0.821
Financials DBV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators DBV
For 52 weeks
0.5 USD
2.14 USD
50 Day MA
0.74 USD
Shares Short Prior Month
321 645
200 Day MA
1.13 USD
Short Ratio
4.77
Shares Short
335 001
Short Percent
0.45 %
BeatStart